Novartis, Elan Sue IPC Over Generic Focalin XR

Law360, New York (March 30, 2011, 5:59 PM ET) -- Novartis Pharma AG and Elan Corp. PLC slapped Intellipharmaceutics Corp. with patent infringement suits in New Jersey and Delaware on Friday over the company's efforts to market a generic version of hyperactivity disorder drug Focalin XR.

Elan's suit, filed in the U.S. District Court for the District of Delaware, targets IPC, Intellipharmaceutics Ltd. and Par Pharmaceuticals Inc. Novartis and Celgene Corp., meanwhile, filed suit in the U.S. District Court for the District of New Jersey, naming IPC as the sole defendant.

Focalin XR is manufactured for...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers